AERINAZE 2.5mg/120mg Tablets/Modified Release

What is AERINAZE 2.5mg/120mg

AERINAZE 2.5mg/120mg is a combination medication presented as modified-release tablets containing two active ingredients: Desloratadine 2.5 mg and Pseudoephedrine sulfate 120 mg. This formulation is designed to treat symptoms associated with seasonal allergic rhinitis, commonly known as hay fever, and other allergic conditions accompanied by nasal congestion.

• Desloratadine: A second-generation, non-sedating antihistamine that alleviates allergic symptoms such as sneezing, itching, watery eyes, and runny nose.
• Pseudoephedrine sulfate: A sympathomimetic decongestant that relieves nasal congestion by constricting swollen nasal blood vessels, thus improving airflow.
• Modified-release tablet: Designed to release the active ingredients gradually, providing extended symptom relief over a 12 to 24-hour period, allowing for convenient once or twice daily dosing.
• Indications: Effective for treating allergic rhinitis symptoms with nasal congestion and improving patient comfort.
• Combination benefit: Targets multiple allergy symptoms simultaneously—histamine-driven symptoms and nasal blockage.

In summary, AERINAZE 2.5mg/120mg offers a comprehensive approach to allergy symptom management, enhancing quality of life during allergy seasons.

How to use AERINAZE 2.5mg/120mg

To maximize the benefits and minimize risks associated with AERINAZE 2.5mg/120mg, it is important to use it correctly as follows:

• Dosage: The usual recommended dose is one modified-release tablet twice daily, approximately 12 hours apart, or as directed by your healthcare provider.
• Administration: Swallow the tablet whole with water; do not crush, chew, or break it, as this may alter the release characteristics and effectiveness of the medication.
• With or without food: Can be taken regardless of meals.
• Timing: Avoid taking late in the day to reduce the risk of insomnia caused by the pseudoephedrine component.
• Missed dose: If you miss a dose, take it as soon as you remember unless it is near the time for your next dose. Do not double doses.
• Duration: Use for the duration recommended by your healthcare provider, generally during the allergy season or as symptoms dictate.
• Precautions: Avoid combining with other decongestants or stimulants without medical advice. Inform your doctor if you are pregnant, breastfeeding, or have chronic medical conditions.

Following these instructions will help optimize symptom control and reduce potential side effects.

Mode of Action AERINAZE 2.5mg/120mg

AERINAZE combines two pharmacologically distinct agents to provide broad symptom relief:

• Desloratadine: Selectively antagonizes peripheral histamine H₁ receptors, preventing histamine binding. This action reduces typical allergy symptoms such as itching, sneezing, rhinorrhea, and conjunctival irritation without causing sedation, as it poorly crosses the blood-brain barrier.
• Pseudoephedrine sulfate: Acts as a sympathomimetic agent stimulating alpha-adrenergic receptors in nasal mucosa blood vessels. This causes vasoconstriction, decreasing nasal mucosal swelling and congestion, facilitating easier breathing through the nose.
• Modified-release mechanism: Ensures steady plasma concentrations of both desloratadine and pseudoephedrine over time, reducing peak-related side effects and improving convenience with fewer doses per day.
• Synergistic effect: The antihistamine targets inflammatory allergic reactions, while pseudoephedrine directly relieves nasal obstruction, together providing comprehensive relief.
• Pharmacokinetics: Desloratadine reaches peak levels within 3 hours, while pseudoephedrine’s vasoconstrictive effects appear rapidly and persist due to the controlled release formulation.

This dual mode of action effectively addresses both the immune response and nasal congestion symptoms characteristic of allergic rhinitis.

AERINAZE 2.5mg/120mg Interactions AERINAZE 2.5mg/120mg

Given its dual components, AERINAZE 2.5mg/120mg can interact with several medications. Careful consideration is required to avoid adverse effects.

• Monoamine oxidase inhibitors (MAOIs): Concurrent or recent use (within 14 days) with MAOIs may lead to hypertensive crisis due to pseudoephedrine's sympathomimetic action.
• Other sympathomimetics: Combining with stimulants (e.g., amphetamines) or decongestants may increase cardiovascular side effects such as increased heart rate and blood pressure.
• Beta-blockers: May reduce the effectiveness of beta-blockers and vice versa; monitor blood pressure and heart rate closely.
• Antihypertensive agents: Pseudoephedrine can reduce the efficacy of medications used to control blood pressure.
• CYP3A4 and CYP2D6 inhibitors: Desloratadine is metabolized via these enzymes; strong inhibitors (e.g., ketoconazole, erythromycin) may increase desloratadine levels, though clinical effects are usually minor.
• Alcohol and CNS depressants: Although desloratadine is minimally sedating, combining with alcohol or sedatives may increase drowsiness or dizziness.
• Other medications: Always inform your healthcare provider about all drugs, supplements, and herbal products you take to prevent unexpected interactions.

Close monitoring and consultation with a healthcare professional are advised when combining AERINAZE with other medications.

Dosage of AERINAZE 2.5mg/120mg

Dosage recommendations for AERINAZE 2.5mg/120mg aim to balance efficacy and safety:

• Adults and adolescents (12 years and older): The usual dose is one modified-release tablet every 12 hours (twice daily), totaling two tablets per day.
• Administration: Tablets should be swallowed whole with water; not to be crushed or chewed to maintain the modified-release properties.
• Children under 12 years: Safety and efficacy have not been established for this age group; use is generally not recommended.
• Elderly patients: Usually no dose adjustment is needed, but caution is advised due to potential cardiovascular sensitivity to pseudoephedrine.
• Patients with renal or hepatic impairment: Dose adjustments may be necessary, especially in severe cases; consult your healthcare provider.
• Duration of treatment: Typically used during symptomatic periods such as allergy seasons or as directed by your healthcare professional.

Always follow your healthcare provider's instructions for dosing to ensure safe and effective treatment.

Possible side effects of AERINAZE 2.5mg/120mg

While effective, AERINAZE 2.5mg/120mg can cause side effects ranging from mild to, rarely, severe. Most side effects are related to either desloratadine or pseudoephedrine components.

• Common side effects:
  • Headache
  • Nervousness or restlessness (pseudoephedrine)
  • Dry mouth
  • Insomnia or difficulty sleeping
  • Dizziness
  • Tachycardia or palpitations
• Less common side effects:
  • Increased blood pressure
  • Gastrointestinal disturbances such as nausea or upset stomach
  • Fatigue or drowsiness (uncommon due to desloratadine)
  • Blurred vision
• Rare but serious side effects:
  • Severe allergic reactions (rash, itching, swelling, difficulty breathing)
  • Chest pain or severe palpitations
  • Hallucinations or severe nervousness
  • Urinary retention
• Precautions: If severe or persistent side effects occur, discontinue use and seek medical attention immediately.

Patients should report any unusual or concerning symptoms to their healthcare provider promptly.

AERINAZE 2.5mg/120mg Contraindications AERINAZE 2.5mg/120mg

To ensure patient safety, AERINAZE 2.5mg/120mg should not be used in the following conditions:

• Hypersensitivity: Known allergy to desloratadine, pseudoephedrine, or any components of the formulation.
• Severe hypertension or coronary artery disease: Pseudoephedrine can exacerbate these conditions due to its vasoconstrictive properties.
• Severe hyperthyroidism: Risk of exacerbated symptoms due to pseudoephedrine’s sympathomimetic effects.
• Patients on monoamine oxidase inhibitors (MAOIs): Use is contraindicated during and within 14 days after MAOI therapy.
• Severe renal or hepatic impairment: Use with caution or avoid due to altered drug metabolism and clearance.
• Glaucoma: Especially angle-closure glaucoma, as pseudoephedrine may increase intraocular pressure.
• Pregnancy and breastfeeding: Should be used only if clearly needed and prescribed by a healthcare professional, as safety data is limited.

Always disclose your full medical history to your healthcare provider to prevent adverse effects.

Storage of AERINAZE 2.5mg/120mg

Proper storage of AERINAZE tablets ensures the medication remains effective and safe:

• Temperature: Store at controlled room temperature between 15°C and 30°C (59°F to 86°F).
• Packaging: Keep the tablets in their original blister packs until use to protect from moisture and contamination.
• Light: Protect from direct sunlight and excessive light exposure.
• Humidity: Avoid storing in bathrooms or damp places to prevent tablet degradation.
• Child safety: Store out of reach and sight of children to avoid accidental ingestion.
• Expiry: Do not use the medication after the expiration date printed on the packaging.
• Disposal: Dispose of expired or unused medication according to local regulations or pharmacy guidelines to ensure safety.

Following these storage instructions maintains the drug’s potency and minimizes risk of harm.